Archives

Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

B Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment Disruptions Array NEW YORK, May 5,… Login to continue reading Login…

Read MoreHoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting

B -Factor advances next-generation allogeneic and in vivo CAR-T cell therapy programs -Presentations will include latest data from Factor’s IL12-expressing iMacrophages for treating solid tumors… Login to continue reading Login…

Read MoreFactor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting

Omnicom Declares Dividend

B NEW YORK, May 5, 2026 /PRNewswire/ — The Board of Directors of Omnicom (NYSE: OMC) declared a quarterly dividend of 80 cents per outstanding share of the… Login to continue reading Login…

Read MoreOmnicom Declares Dividend